FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Nutrition & Health News

Drink your vitamins: SternVitamin launches micronutrient premix for beverages 

19 Feb 2018 --- A healthy lifestyle is essential to all age groups, and nutrition plays a major role alongside various other components. SternVitamin is now offering beverage manufacturers a novel way to address the topic of health with a new micronutrient premix for healthy bones and heart. SternVitamin notes that the mix picks up on one of the top trends in the beverage market – water-based enriched products. The vegan premix contains vitamins B1, B12, C, K2 and D3. Organic agave syrup powder gives it a slight sweetness, while natural flavors give the drink a “dark berry” taste. It dissolves clear in water and leaves no turbidity. 

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

L-Carnitine – "Unquestionable" room for market growth: Lonza

08 Feb 2018 --- From facilitating the recovery process in the sports nutrition sector to improving energy metabolism in healthy aging products, L-Carnitine has proven itself a versatile ingredient with the potential to be applied in myriad applications. “Sports nutrition, weight management, all these areas are still growing. There is no question that there is a lot of room for L-Carnitine’s development. We see a lot of demand coming from Asia and Africa for infant food applications. The other big market is for sure energy drinks,” Marco Gossen, Business Development Manager at Lonza, explains during a NutritionInsight webinar last week, looking at product development and untapped opportunities for L-Carnitine.

Business News

Probi signs agreement with “global FMCG company” on gut health launch, enjoys Asia-Pacific growth

26 Jan 2018 --- Probi is seeking to further expand into the functional food space with a newly signed agreement with an as-of-yet unnamed global FMCG company. The partnership relates to the launch of a product containing Probi’s bacteria for gut health in North America. In its year-end report, Probi [which is majority owned by Symrise] notes that a launch in the North American market is planned for the second half of 2019, potentially followed by launches in other territories. The agreement is expected to have a significant impact on future sales and earnings in Probi’s Functional Food business area. 

Nutrition & Health News

Banken Champignons to launch vitamin D mushrooms 

26 Jan 2018 --- Dutch mushroom supplier Banken Champignons has received a green light from the European Food Safety Authority (EFSA) to launch vitamin D mushrooms on the European market. According to the company, a single serving of this new mushroom variant can provide the RDA of 10 micrograms of vitamin D. 

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html